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Abstract
Background: COX-2 expression in tumour cells has been associated with poor prognosis in
gastrointestinal and non-gastrointestinal cancers. The aim of our study was to test the hypothesis
that higher levels of COX-2 expression are prognostically related to poor clinico-pathologic
features in adenocarcinoma of the oesophagus.
Methods:  We reviewed the records of 100 consecutive patients undergoing resection for
adenocarcinoma of the oesophagus to collect data on T-stage, N-stage, tumour recurrence and
survival. T & N-stage was further confirmed by histological examination. COX-2 protein
expression was assessed by immunohistochemistry in all patients and COX-2 m-RNA expression
was measured by quantitative RT-PCR in a small group of patients.
Results: Higher levels of COX-2 expression were associated with higher T stage (p = 0.008),
higher N stage (p = 0.049), increased risk of tumour recurrence (p = 0.01) and poor survival (p =
<0.001). A COX-2 score of >200 was associated with a median survival of 10 months compared
to 26 months with a score of <200 (p = <0.001).
Conclusion: Higher levels of COX-2 expression are associated with poor clinico-pathologic
features and poor survival in patients with oesophageal adenocarcinoma.
Background
Oesophageal adenocarcinoma is an aggressive human
malignancy. It is of particular concern that the incidence
of oesophageal adenocarcinoma is increasing more rap-
idly then any other cancer in Western Europe and the
United States[1]. It has an incidence of 7.4 per 100,000 in
England and Wales and accounts for 5,600 deaths annu-
ally [2,3]. The only hope of cure is complete surgical resec-
tion with or without neo-adjuvant chemotherapy.
Endoscopic ultrasound has improved the accuracy of local
staging leading to better patient selection for curative
resection and estimating prognosis. Unfortunately, the 5-
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year survival rate is only 25% even after intentionally cur-
ative resection with a median survival of 15–18
months[4]. Developing better prognostic markers and
effective treatment strategies depends on our understand-
ing of the biological behaviour of these tumours and iden-
tifying factors responsible for tumour invasiveness,
metastasis and recurrence.
Epidemiologic studies show that non-steroidal anti-
inflammatory drugs (NSAIDs) can reduce the incidence
and mortality from gastrointestinal malignancy, includ-
ing oesophageal, gastric and colonic cancers[5]. This sug-
gests a pathogenic role of cyclooxygenase (COX), the
principle target enzyme for the actions of NSAIDs, in gas-
trointestinal tumourigenesis. COX is a rate-limiting
enzyme involved in the conversion of arachidonic acid to
prostaglandins, prostacyclin, and thromboxanes. Two
COX genes, COX-1 and COX-2 have been identified,
which share over 60% identity at the amino acid level[6].
COX-1 is constitutively expressed in many tissues and
responsible for various physiological functions[7]. COX-2
is not universally expressed by all tissues but can be
induced by various pathologic stimuli, such as inflamma-
tion, cytokines and various growth factors produced by
tumour cells [8-10]. Increased expression of COX-2 has
been demonstrated in various inflammatory diseases[11]
and malignancies of the colon[12] stomach[13], liver[14],
pancreas[15] and oesophagus[16]. Overexpression of
COX-2 in human carcinomas seems to be of functional
significance as double knockout mice for APC and COX-2
genes showed marked reduction in the size and frequency
of intestinal polyps[17]. This anti-neoplastic effect of
COX-2 inhibitors was further confirmed when they were
found to reduce polyp burden in patients with familial
adenomatous polyposis[18]. There is also cumulative evi-
dence that selective COX-2 inhibitors prevent carcinogen-
esis in experimental animals[19], and that these
compounds induce apoptosis[20], inhibit angiogen-
esis[21] and growth[22] in several types of cancer cells.
These findings suggest that COX-2 may be associated with
carcinogenesis and progression of certain types of human
malignancies. However, the prognostic significance of
COX-2 expression in human oesophageal carcinoma
remains unclear. The clinicopathologic significance of
COX-2 in oesophageal carcinoma has been reported
recently with conflicting results [23-26]. We have further
evaluated the role of COX-2 in patients with adenocarci-
noma of oesophagus. The aim of our study was to test the
hypothesis that higher levels of COX-2 expression are
related to higher pathological tumour stage and poor clin-
ical outcome in adenocarcinoma of oesophagus.
Methods
Patient population
We reviewed the records of 100 consecutive patients with
adenocarcinoma of oesophagus that underwent oesopha-
geal resection with curative intent at our institute between
1990–96. The data was collected in 2001 to ensure a min-
imum follow-up of 5 years (range: 5–11 yr). None of these
patients received preoperative chemotherapy or irradia-
tion. Preoperative work up included gastroscopy with
biopsy, abdominal ultrasound, chest X-ray and CT scan
(selected cases) of chest and abdomen. All these patients
underwent Ivor lewis oesophagectomy. We excluded
patients with squamous cell cancer of oesophagus, aden-
ocarcinomas crossing the gastroesophageal junction and
those with distant metastasis. All pathology reports and
archival material from these patients were reviewed by
one of the investigators (ACB) to ascertain the T-stage, N-
stage and to identify the block with deepest invasion of
tumour. Recurrence and survival data were obtained from
the case notes as these patients were followed up regularly
in the outpatient clinics.
We prospectively collected fresh tissue biopsies from a
separate group (not a part of the 100 consecutive patiets)
of sixteen consecutive patients with oesophageal adeno-
carcinoma to compare COX-2 m-RNA expression, meas-
ured by quantitative RT-PCR with COX-2 protein
expression, measured by immunohistochemistry.
The study was approved by the Southampton and South
West Hants Local Research Ethics Committee. (ref:292/
01)
Immunohistochemistry
The resection specimens were fixed in 10% buffered for-
malin and embedded in paraffin wax. Four micron sec-
tions were cut from each block and mounted onto glass
slides before being de-paraffinised and then immersed in
0.3% H2O2 in methanol for 10 minutes to block endog-
enous peroxidase activity. The sections were pressure
cooked for 12 minutes in citrate buffer (pH 6.1) for anti-
gen retrieval. Visualisation of the bound primary antibod-
ies was performed using AEC as a chromogen.
Antigen adsorption studies were performed using COX-2
blocking peptide. The sections were treated in the same
manner as above except that COX-2 antibody was prein-
cubated with 10 mcg/ml COX-2 blocking peptide at room
temperature for one hour. Positive controls (tonsil) were
used for each run and a negative control (primary anti-
body replaced by TBS) was included for each section.
Scoring was performed using an intensity-proportion
scoring system, as previously described for immuno-scor-
ing of oestrogen receptors in breast carcinoma[27] and
recently adapted by us for immuno-scoring in upper gas-BMC Cancer 2006, 6:134 http://www.biomedcentral.com/1471-2407/6/134
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trointestinal biopsies[28]. The percentage of positively
labelled cells (0–100%) in each section was multiplied by
the intensity of labelling, graded from 0 (no labelling) to
3 (intense labelling), providing a score between 0 and
300. In adenocarcinoma of oesophagus, it is not known if
intensity of staining is more significant then the propor-
tion of cells staining positive or vice versa so we decided
to use this system that can take account of both the inten-
sity and proportion of positively staining cells.
The primary antibody to COX-2 (Cat. No. 160112) and
the blocking peptide for COX-2 (Cat.No. 360107) were
sourced from Cayman Chemical Company (Ann Arbor,
Michigan, USA).
Reproducibility and scoring validation
During our initial experiments, we stained a group of 10
specimens on three separate occasions to ascertain the
reproducibility of the COX-2 staining. After a time in
Representative examples of COX-2 immunhistochemistry in adenocarcinoma of oesophagus Figure 1
Representative examples of COX-2 immunhistochemistry in adenocarcinoma of oesophagus. (A) low level (<200) and (B) high 
level (>200)of COX-2 expression. Antigen adsorption study demonstrated good immunoreactivity with COX-2 antibody (C) 
and lack of immunoreactivity when staining was repeated in the presence of COX-2 blocking peptide (D).
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excess of 3 months, 10 sections were selected at random
and rescored to assess the intraobserver variation in scor-
ing. This was carried out by the original investigator with-
out prior knowledge of the clinicopathologic
characteristics of the tumour or the previous COX-2 score.
Quantitative RT-PCR
Tumor cells were obtained after enzymatic dissociation
from endoscopic oesophageal biopsies and were resus-
pended in RNA later (Ambion). Cells were stored at -80°C
until total RNA was extracted with a commercially availa-
ble kit (NucleoSpin® RNA II mini, Macherey-Nagel, Ger-
many, Cat. 740955) following manufacturer's
instructions. Total RNA was then reverse-transcribed by
using the Promega reverse transcription system (Promega,
Southampton, UK, Cat # A3500). The resulting c-DNA
was amplified by real-time quantitative PCR on a Biorad
iCycler instrument (BioRad Laboratories, Hemel Hamp-
stead, UK) using SYBR Green PCR buffer (SYBR Green
PCR Core Reagents, Applied Biosystems, P/N 4304886).
The following primers (400 nM) were used for COX-2
detection (forward 5'-CCTTCCTCCTGTGCCTGATG;
reverse 5'-ACAATCTCATTTGAATCAGGAAGCT), as previ-
ously described (Sales et al., 2002). It is well known that
mRNA levels of commonly used house keeping genes vary
between individuals and the use of a single housekeeping
gene within a qRT-PCR system is not sufficient. (Vandes-
ompele et al., 2002) At least three out of the following
four housekeeping genes were used for each experiment:
glyceraldehyde-3 phosphate dehydrogenase (GAPDH),
hypoxanthine phosphoribosyltransferase 1 (HPRT1),
human porphobilinogen deaminase (PBGD) and TATA
box binding protein (TBP). A positive control (pooled c-
DNA from a variety of human tumors, including breast,
ovarian, colorectal and oesophageal carcinoma) and neg-
ative controls with no template and RT-negative as tem-
plate were added in every experiment. All assays were run
in triplicate. A comparative Ct (cycle threshold) method
was employed to measure relative gene expression (ABI
PRISM 7700 User Bulletin #2, 2001 update). The follow-
ing formula was used to calculate the relative amount of
the transcript in the sample: 2-∆Ct, where ∆Ct is the differ-
ence in Ct between the gene of interest (COX-2) and the
mean of the two most stable and therefore most appropri-
ate house keeping/reference genes.
Immunostaining vs RT-PCR
In 16 patients prospective biopsies were used to assess the
COX-2 protein expression by immuno-staining and COX-
2 m-RNA by RT-PCR. These values were then compared to
assess the relationship between COX-2 m-RNA and pro-
tein expression.
Correlation between COX-2 m-RNA and COX-2 protein expression in biopsies from oesophageal adenocarcinoma Figure 2
Correlation between COX-2 m-RNA and COX-2 protein expression in biopsies from oesophageal adenocarcinoma.
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Statistics
Statistical analysis was performed using SPSS 11.0 soft-
ware. The association between demographic, clinico-
pathologic features and COX-2 was analysed using the
student t test (continuous data) and chi square test (cate-
gorical data). Analysis of variance was performed and
Fishers exact test was performed whenever necessary. The
Cox proportional hazards model was used to examine the
effect of COX-2 expression in relation to other prognostic
factors. A p-value of 0.05 or less was considered to be sta-
tistically significant.
Results
Clinical data
Out of the 100 consecutive patients who underwent
potentially curative surgery for adenocarcinoma of
oesophagus, 6 patients died within 1 month (overall 30
day mortality of 6%) and 4 patients did not have clear
(cancer free) resection margins so were excluded from sur-
vival analysis. We therefore performed the survival analy-
sis on the data obtained from 90 patients (M: 81, F: 9)
with a mean age of 65 yrs (39–83 yrs). The data on
Tumour and Nodal stage of the tumours is shown in
table-2. In 16 patients, we collected prospective biopsies
and compared COX-2 m-RNA expression (RT-PCR) with
COX-2 protein expression.
Correlation between survival and clinicopathologic parameters: Kaplan-Meier curves comparing survival with tumour invasion  (A), nodal metastasis (B) and tumour recurrence (C) Figure 3
Correlation between survival and clinicopathologic parameters: Kaplan-Meier curves comparing survival with tumour invasion 
(A), nodal metastasis (B) and tumour recurrence (C). Linear regression (D) analysis showing negative correlation between sur-
vival and COX-2 expression.
(A)
02 0 4 0 6 0 8 0 1 0 0
Survival Time (months)
0.0
0.2
0.4
0.6
0.8
1.0
C
u
m
m
u
l
a
t
i
v
e
 
p
r
o
b
a
b
i
l
i
t
y
 
o
f
 
s
u
r
v
i
v
a
l
T-Stage
T2
T3
(B) 
02 0 4 0 6 0 8 0 1 0 0
Survival Time (months)
0.0
0.2
0.4
0.6
0.8
1.0
C
u
m
m
u
l
a
t
i
v
e
 
p
r
o
b
a
b
i
l
i
t
y
 
o
f
 
s
u
r
v
i
v
a
l
N - Stage
.00
1.00
(C)
02 0 4 0 6 0 8 0 1 0 0
Survival Time (months)
0.0
0.2
0.4
0.6
0.8
1.0
C
u
m
m
u
l
a
t
i
v
e
 
p
r
o
b
a
b
i
l
i
t
y
 
o
f
 
s
u
r
v
i
v
a
l
Tumour Recurrence
None
Present
(D) 
0 50 100 150 200 250 300
COX-2 staining score
0
20
40
60
80
100
S
u
r
v
i
v
a
l
 
T
i
m
e
 
(
m
o
n
t
h
s
)
p=<0.001
p=<0.001
r=0.407 
p=0.003 
p=<0.001BMC Cancer 2006, 6:134 http://www.biomedcentral.com/1471-2407/6/134
Page 6 of 9
(page number not for citation purposes)
COX-2 expression
COX-2 expression was seen in all patients (100%) and
was primarily expressed by tumour cells. The degree of
expression was variable but the median COX-2 score was
200 and we used this as a threshold value with fig-1(A)
demonstrating low (<200) and fig1(B) demonstrating
high (>200) levels of expression. The antigen adsorption
study demonstrated the specificity of our antibody by
showing good immunoreactivity (fig-1(C)) with COX-2
antibody and complete blockage of this immunoreactivity
(fig-1(D)) when staining was repeated in the same speci-
men with COX-2 antibody preincubated with COX-2
blocking peptide. The specificity of our antibody was fur-
ther confirmed by the lack of staining seen in our negative
controls (primary antibody replaced by TBS).
Reproducibility and scoring validation
The 10 specimen that were stained on three separate occa-
sions showed a very good reproducibility for COX-2 stain-
ing. Of the 10 sections being rescored, we found that
intensity score was correctly reproduced in all 10 and the
proportion score was correctly reproduced in 7 sections.
The remaining 3 sections, which were incorrectly scored,
were all from the low COX-2 expressing group but the dis-
crepancies were small, giving an average error of <5%.
Correlation between COX-2 protein and COX-2 m-RNA 
expression
Fig-2 shows a positive correlation (R2 = 0.021) between
COX-2 m-RNA expression, assessed by RT-PCR and COX-
2 protein expression, assessed by immunohistochemistry
in oesophageal biopsies from patients with adenocarci-
noma of oesophagus.
Correlation between survival and clinico-pathologic 
parameters
Fig-3 shows the relationship between survival and clinico-
pathologic factors. We confirmed a significant correlation
between survival and traditional prognostic factors
including the depth of tumour invasion or T-stage (fig 3-
A), nodal metastasis or N-stage (fig 3-B) and tumour
recurrence (fig 3-C). We also demonstrated (fig 3-D) a sig-
nificant negative correlation between patient survival and
COX-2 expression in the oesophageal biopsies taken from
the tumour sites (p = <0.001). On further analysis we
identified that using our scoring system a COX-2 expres-
sion score of (≥200) served as a good marker of poor sur-
vival, with a median survival time of 10 months as
compared to 26 months in patients with COX-2 expres-
sion <200 (p = <0.001) as shown in fig-4.
Kaplan-Meier survival curves according to COX-2 expression illustrates a poor survival (median survival of 10 mths) in patients  with tumours expressing High (≥200) levels of COX-2 and better survival (median survival of 26 mths) in those with Low  (<200) levels of COX-2 Figure 4
Kaplan-Meier survival curves according to COX-2 expression illustrates a poor survival (median survival of 10 mths) in patients 
with tumours expressing High (≥200) levels of COX-2 and better survival (median survival of 26 mths) in those with Low 
(<200) levels of COX-2.
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We performed univariate and multivariate survival analy-
sis using Cox proportional Hazards model and confirmed
that higher T-stage, N-stage and COX-2 score were inde-
pendent markers of survival (table-1)
Correlation between clinicopathologic characteristics and 
COX-2 expression
Table-2 illustrates that higher levels of COX-2 expression
were associated with higher T-stage (p = 0.008), higher N-
stage (p = 0.049), poorly differentiated tumour on histol-
ogy (p = 0.045) and higher incidence of tumour recur-
rence (p = 0.01) after potentially curative resection of
adenocarcinoma of oesophagus.
Discussion
Our results demonstrate that the COX-2 enzyme is univer-
sally expressed in adenocarcinoma of oesophagus but the
amount of COX-2 expression is variable. Tumours
expressing high levels of COX-2 are associated with poor
patient survival after surgery. We also demonstrated a rela-
tionship between COX-2 expression and higher T and N
stage as well as increased risk of tumour recurrence after
curative resection. On further analysis we identified a cut
off score of ≥200 for COX-2 expression, which could serve
as a marker of aggressive disease and poor survival. We
demonstrated a positive correlation between COX-2 m-
RNA expression detected by PCR and COX-2 protein
expression detected by immunohistochemistry in patients
with oesophageal adenocarcinoma. This further strength-
ens the validity of our immuno-scoring system and shows
a link between genomics and proteomics.
We evaluated COX-2 expression by immunohistochemis-
try as this is one of the most widely used method that can
be used to analyze protein expression in paraffin embed-
ded archival material. Using immunohistochemistry, the
signal can be precisely localized to the tumour cell which
is not possible when using other techniques like immuno-
blot and PCR which can overestimate COX-2 expression
by identification of expression within both inflammatory
and neoplastic cells. One of the strengths of our work is
the specificity of our antibody, as demonstrated by the
absence of staining in the antigen adsorption study and in
the negative controls. Quantification of protein expres-
sion may be difficult when using immunohistochemistry.
However, we used an intensity-proportion scoring system
which has been extensively used in breast cancer scor-
ing[28]. We found that this scoring system was very easy
to use and highly reproducible. The strength of our scor-
ing system was further confirmed by our PCR data, which
showed a positive correlation between RT-PCR quantifica-
tion and immuno-scoring for COX-2.
The literature is fairly divided on the clinicopathologic sig-
nificance of COX-2 in oesophageal cancer. There are two
studies addressing this issue in patients of Japanese origin
with squamous cell cancer of oesophagus and have demon-
strated a lack of correlation between COX-2 expression and
clinicopathologic features of the tumour or overall survival
[24,25]. Two additional studies have been performed in
patients of western origin with adenocarcinoma of
oesophagus and like our study have demonstrated a nega-
tive correlation between levels of COX-2 expression and
overall survival, although unlike our study no correlation
was found between COX-2 expression and clinicopatho-
logic features of the tumour and no attempt was made to
correlate the COX-2 protein expression with the COX-2 m-
RNA expression[23,26]. Our study substantiates the find-
Table 2: Correlation between COX-2 expression and 
clinicopathologic characteristics* Log rank test
Cox-2 score p value*
T-stage
T-2 (n = 11) 124.55
T-3 (n = 79) 199.50 0.008
N-stage
N-0 (20) 156.00
N-1 (70) 200.14 0.049
Tumour recurrence
No (22) 99.54
Yes (55) 226.72 0.01
Tumour differentiation
Well (11) 134.50
Poor/moderate (79) 198.00 0.045
Table 1: Univariate and Multivariate analysis of survival related clinicopathologic parameters by the Cox Proportional Hazards Model
Univariate Multivariate
n = 90 RR 95% CI p-value RR 95% CI p-value
Age 1.01 0.98 – 1.03 0.620 1.02 0.99 – 1.04 0.120
Male gender 0.85 0.40 – 1.78 0.660 1.51 0.69 – 3.28 0.300
Higher T-stage (>T2) 2.79 1.41 – 5.51 0.003 2.25 0.92 – 5.14 0.060
Higher N-stage (>N0) 2.96 1.58 – 5.54 <0.001 2.30 1.25 – 4.23 0.010
Poorly differentiated tumour 1.78 0.94 – 3.36 0.077 1.53 0.73 – 3.20 0.260
High COX-2 score (≥200) 3.53 2.11 – 5.89 <0.001 2.91 1.78 – 4.76 <0.001BMC Cancer 2006, 6:134 http://www.biomedcentral.com/1471-2407/6/134
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ings of these previous studies and gives a better insight into
the link between the clinico-pathologic features and COX-
2 expression in adenocarcinoma of oesophagus. However,
another previous study by Lagorce et al [34] found that
COX-2 is expressed predominantly in well differentiated
adenocarcinoma and did not find any correlation between
COX-2 expression and patient survival or any of the clin-
icopathologic features of the tumour. It is difficult to
explain the differences in the findings of this study as com-
pared to ours and the other two studies. However, the study
by Lagorce et al included patients with distant metastasis
and grouped moderate and well differentiated tumours
together producing a slightly skewed distribution in favour
of poor differentiation (47 vs 19). Our study excluded
patients with distant metastasis and grouped moderate and
poorly differentiated tumours together to produce a skew
in favour of well differentiation (79 vs 11). These differ-
ences in patient selection and study design might explain
the differences in results.
The strengths of our study include the large number of
enrolled consecutive patients with adenocarcinoma of
oesophagus, the use of immunohistochemistry to pre-
cisely localise the expression in the neoplastic cells, the
use of resection specimens rather then superficial biopsies
(as biopsies could underestimate the expression of COX-
2 due to its heterogenous nature of expression), the dem-
onstration of a positive link between COX-2 protein
(immunohistochemistry) and m-RNA (PCR) expression
and the specificity of our antibody as shown by the
absence of staining in negative controls and during anti-
gen adsorption study.
Given the current literature and the findings of our study it
can be concluded that the prognostic significance of COX-
2 overexpression in oesophageal cancer varies with the his-
tological subtype of the tumour, a negative prognostic
influence in adenocarcinoma but with no prognostic influ-
ence in squamous cell cancer. This raises the possibility that
the biological behaviour of the oesophageal cancer might
vary with the histological type of the tumour.
It is not clear from our study whether COX-2 plays a pri-
mary role in carcinogenesis and progression or is simply a
para-phenomenon. However, a primary role of COX-2 is
consistent with the epidemiological data linking
increased survival and reduced incidence of oesophageal
cancer and NSAID use[5]. The precise mechanism for the
survival disadvantage observed in patients with high lev-
els of COX-2 is not clear but it is well established that can-
cer cells expressing high levels of COX-2 have a higher rate
of proliferation and a lower rate of apoptosis[29]. Selec-
tive inhibition of COX-2 reduces tumourigenesis in differ-
ent models of carcinogenesis[17,19,30]. Thus, COX-2 has
been shown to play a causal role in carcinogenesis. Fur-
thermore, COX-2 expression has been linked to enhanced
levels of angiogenesis[31] and expression of metallopro-
teinases[32] resulting in an increased invasiveness and
metastatic potential of tumours. This is further demon-
strated by the effect of COX-2 inhibitor in suppressing the
haematogenous metastasis of colon cancer in mice[33].
Our study demonstrates an association between high lev-
els of COX-2 expression and higher T-stage, N-stage and
an increased risk of tumour recurrence after potentially
curative resection. These are all features of a tumour with
increased malignant and metastatic potential and this
might be one of the mechanisms explaining the link
between poor survival and increased COX-2 expression.
However, on multivariate analysis we found that the effect
of COX-2 on survival was independent of T and N stage.
This raises the possibility that there may be other mecha-
nisms by which COX-2 adversely influences survival.
The adverse influence of COX-2 on patient survival has
also been reported in other gastrointestinal tumours like
the stomach and colon but none of these studies elucidate
the mechanisms behind the influence of COX-2 on sur-
vival, which still remains a matter for future research.
Conclusion
This is the first report on higher levels of COX-2 expres-
sion being linked to higher T and N stage of tumour,
increased risk of tumour recurrence and reduced survival
in adenocarcinoma of oesophagus. Although no conclu-
sions with regard to treatment can be drawn from these
findings, it does suggest that COX-2 may play a role in
increasing the malignant potential of adenocarcinoma of
oesophagus. These findings justify the need to initiate
future clinical studies exploring the role of COX-2 inhibi-
tors in the treatment of adenocarcinoma of oesophagus
with the intention of improving survival. We also believe
that estimation of COX-2 expression may serve as a prog-
nostic tool in clinical practice and future interventional
research aimed at improving survival in patients with ade-
nocarcinoma of oesophagus.
Abbreviations
COX: Cyclooxygenase, NSAID: Nonsteroidal anti inflam-
matory drug
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
PB: Conception, design, data acquisition, data analysis,
data interpretation and drafting manuscript
ACB, RLM, PP: design, data analysis and drafting manu-
scriptBMC Cancer 2006, 6:134 http://www.biomedcentral.com/1471-2407/6/134
Page 9 of 9
(page number not for citation purposes)
BSFS, PJ, FDN: data acquisition
IAC: data acquisition, drafting manuscript
All authors read and approved the final manuscript
Acknowledgements
We are grateful to Prof A Sampson (Clinical Pharmacology, Southampton 
University Hospital) for his technical help with Immunohistochemistry and 
Surgeons who submitted material from the patients to make this study pos-
sible.
We are also grateful to Wessex Cancer Trust for providing the research 
grant to support the consumable expenses.
References
1. Blot WJ: Esophageal cancer trends and risk factors.  Semin
Oncol 1994, 21:403-10.
2. Smans M, Muir CS, Boyle P, Smans M, Muir CS, Boyle P, editors: Atlas
of cancer mortality in the EEC.  Lyon: International agency for
research on cancer 1992.
3. Mathews HR, Waterhouse JAH, Powell J, McConkey CC, Robertson
JE, Editors: Cancer of the oesophagus.  In Clinical cancer mono-
graphs vol London: Macmillan; 1987. 
4. Greenlee RT, Hill-Harmon MB, Murray T, Thun M: Cancer statis-
tics, 2001.  CA Cancer J Clin 2001, 51:15-36.
5. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW Jr:
Aspirin use and risk of fatal cancer.  Cancer Res 1993,
53(6):1322-7.
6. Hla T, Neilson K: Human cyclooxygenase-2 cDNA.  Proc Natl
Acad Sci U S A 1992, 89(16):7384-8.
7. Vane J: Towards a better Aspirin.  Nature 1994, 367:215-6.
8. Lee SH, Soyoola E, Chanmugam P, Hart S, Sun W, Zhong H, Liou S,
Simmons D, Hwang D: Selective expression of mitogen induci-
ble cyclooxygenase in macrophages stimulated with lipopol-
ysacharide.  J Biol Chem 1992, 267:25934-8.
9. Sakamoto C, Matsuda K, Nakano O, Konda Y, Matozaki T, Nishisaki
H, Kasuga M: EGF stimulates both cyclooxygenase activity and
cell proliferation in cultured guinea pig gastric mucus cells.  J
Gastroenterol 1994, 29(7):73-6.
10. Jones DA, Carlton DP, McIntyre TM, Zimmerman GA, Prescott SM:
Molecular cloning of human prostaglandin endoperoxide
synthase type II and demonstration of expression in
response to cytokines.  J Biol Chem 1993, 268(12):9049-54.
11. Singer II, Kawka DW, Schloemann S, Tessner T, Riehl T, Stenson WF:
Cyclooxygenase 2 is induced in colonic epithelial cells in
inflammatory bowel disease.  Gastroenterology 1998,
115(2):297-306.
12. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S,
DuBois RN: Up-regulation of cyclooxygenase 2 gene expres-
sion in human colorectal adenomas and adenocarcinomas.
Gastroenterology 1994, 107(4):1183-8.
13. Ristimaki A, Honkanen N, Jankala H, Sipponen P, Harkonen M:
Expression of cyclooxygenase-2 in human gastric carcinoma.
Cancer Res 1997, 57:1276-1280.
14. Koga H, Sakisaka S, Ohishi M, Kawaguchi T, Taniguchi E, Sasatomi K,
Harada M, Kusaba T, Tanaka M, Kimura R, Nakashima Y, Nakashima
O, Kojiro M, Kurohiji T, Sata M: Expression of cyclooxygenase-2
in human hepatocellular carcinoma: relevance to tumor
dedifferentiation.  Hepatology 1999, 29(3):688-96.
15. Tucker ON, Dannenberg AJ, Yang EK, Zhang F, Teng L, Daly JM,
Soslow RA, Masferrer JL, Woerner BM, Koki AT, Fahey TJ: Cycloox-
ygenase-2 expression is up-regulated in human pancreatic
cancer.  Cancer Res 1999, 59(5):987-90.
16. Wilson KT, Fu S, Ramanujam KS, Meltzer SJ: Increased expression
of inducible nitric oxide synthase and cyclooxygenase-2 in
Barrett's esophagus and associated adenocarcinomas.  Cancer
Res 1998, 58(14):2929-2934.
17. Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E,
Trzaskos JM, Evans JF, Taketo MM: Suppression of intestinal poly-
posis in Apc delta716 knockout mice by inhibition of cycloox-
ygenase 2 (COX-2).  Cell 1996, 87(5):803-9.
18. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon
GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK, Levin B:
The effect of celecoxib, a cyclooxygenase-2 inhibitor, in
familial adenomatous polyposis.  N Engl J Med 2000,
342(26):1946-52.
19. Kawamori T, Rao CV, Seibert K, Reddy BS: Chemopreventive
activity of celecoxib, a specific cyclooxygenase-2 inhibitor,
againstcolo carcinogenesis.  Cancer Res 1998, 58(3):409-12.
20. Hara A, Yoshimi N, Niwa M, Ino N, Mori H: Apoptosis induced by
NS-398, a selective cyclooxygenase-2 inhibitor, in human
colorectal cancer cell lines.  Jpn J Cancer Res 1997, 88(6):600-4.
21. Sawaoka H, Tsuji S, Tsujii M, Gunawan ES, Sasaki Y, Kawano S, Hori
M:  Cyclooxygenase inhibitors suppress angiogenesis and
reduce tumor growth in vivo.  Lab invest 1999, 79(12):1469-77.
22. Sawaoka H, Kawano S, Tsuji S, Tsujii M, Gunawan ES, Takei Y, Nagano
K, Hori M: Cyclooxygenase-2 inhibitors suppress the growth
of gastric cancer xenografts via induction of apoptosis in
nude mice.  Am J Physiol 1998, 274:1061-1067.
23. Buskens CJ, Van Rees BP, Sivula A, Reitsma JB, Haglund C, Bosma PJ,
Offerhaus GJ, van Lanschot JJ, Ristimaki A: Prognostic significance
of elevated cyclooxygenase 2 expression in patients with
adenocarcinoma of the esophagus.  Gastroenterology 2002,
122(7):1800-7.
24. Shamma A, Yamamoto H, Doki Y, Okami J, Kondo M, Fujiwara Y,
Yano M, Inoue M, Matsuura N, Shiozaki H, Monden M: Up-regula-
tion of cyclooxygenase-2 in squamous carcinogenesis of the
esophagus.  Clin Cancer Res 2000, 6(4):1229-38.
25. Nozoe T, Ezaki T, Kabashima A, Baba H, Kabashima A: Significance
of immunohistochemical expression of COX-2 in squamous
cell carcinoma of the esophagus.  Am J Surg 2005, 189(1):110-5.
26. France M, Drew PA, Dodd T, Watson DI: Cyclo-oxygenase-2
expression in esophageal adenocarcinoma as a determinant
of clinicaloutcome following esophagectomy.  Dis Esophagus
2004, 17(2):136-40.
27. Kinsel LB, Szabo E, Greene GL, Konrath J, Leight GS, McCarty KS:
Immunocytochemical analysis of estrogen receptors as a
predictor of prognosis in breast cancer patients: comparison
with quantitative biochemical methods.  Cancer Reseach 1989,
49(4):1052-6.
28. Bhandari P, Bateman AC, Mehta RL, Patel P: Mucosal expression of
cylooxygenase isoforms 1 and 2 is increased with worsening
damage to the gastric mucosa.  Histopathology 2005, 46:280-86.
29. Souza RF, Shewmake K, Beer DG, Cryer B, Spechler SJ: Selective
inhibition of cylooxygenase-2 suppresses growth and induces
apoptosis in human esophageal adenocarcinoma cells.  Cancer
Research  2000, 60:5767-72.
30. Reddy BS, Rao CV, Seibert K: Evaluation of COX-2 inhibitor for
potential chemopreventive properties in colon carcinogene-
sis.  Cancer Research 1996, 56:4566-69.
31. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN:
Cyclooxygenase regulates angiogenesis induced by colon
cancer cells.  Cell 1998, 93:705-16.
32. Dohadwala M, Batra RK, Luo J, Lin Y, Krysan K, Pold M, Sharma S,
Dubinett SM: Autocrine/paracrine prostaglandin E2 produc-
tion by non-small cell lung cancer cells regulates matrix met-
alloproteinase-2 and CD44 in cox-2 dependent invasion.  J Biol
Chem 2002, 277(52):50828-33.
33. Tomozawa S, Nagawa H, Tsuno N, Hatano K, Osada T, Kitayama J,
Sunami E, Nita ME, Ishihara S, Yano H, Tsuruo T, Shibata Y, Muto T:
Inhibition of haematogenous metastasis of colon cancer in
mice by a selective COX-2 inhibitor, JTE-522.  Br J Cancer 1999,
81:1274-79.
34. Lagorce C, Paraf F, Vidaud D, Couverlard A, Wendum D, Martin A,
Flejou J-F: Cyclooxygenase-2 is expressed frequently and early
in Barrett's oesophagus and associated adenocarcinoma.
Histopatholog 2003, 2:457-65.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/6/134/pre
pub